Lonza Group AG (LZAGF) Stock Price & Analysis
Lonza Group AG (LZAGF) — price $660.00 (-3.26%), as of the Oct 2, 2026 trading session; market cap $46.1B.
Educational signal · not a buy or sell recommendation · How to read this
Lonza Group AG · LZAGF · Healthcare · Biotechnology
Lonza Group AG, established in 1897 and based in Basel, Switzerland, is a global enterprise that furnishes critical products and services to the pharmaceutical, biotechnology, and nutrition sectors.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $660.00 | |
| Change on the day | -3.26% | |
| 52-week range | $565.14–$755.96 | |
| Market capitalisation | $46.1B | |
| Shares traded on the day | 27 | |
| Beta (volatility vs the S&P 500) | 0.84 | |
| Dividends per share (last 12 months) | $6.39 | |
| Dividend yield (last 12 months) | 0.97% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Management outlook
Until 2030, based on our organic growth model, we intend to invest more than CHF 7 billion in organic CapEx, with the majority of it dedicated to future growth.
Wolfgang Wienand · Statement from
However, we anticipate that this will be offset in H2 due to the extended shutdown to progress with the site's CapEx measures, with full year 2026 sales expected to be broadly flat versus full year 2025 at around CHF 0.6 billion.
Wolfgang Wienand · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations can change.
Source recordsOther perspectives
Council score for Lonza Group AG (LZAGF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the LZAGF film — every key number, told as a short cinematic story
~2 min · open the film
What is Lonza Group AG (LZAGF), and what does it report?
Short answer · as of
Lonza Group AG, established in 1897 and based in Basel, Switzerland, is a global enterprise that furnishes critical products and services to the pharmaceutical, biotechnology, and nutrition sectors. Lonza Group AG (LZAGF) is classified as Healthcare / Biotechnology. Headquarters: Muenchensteinerstrasse 38, Basel, BS, 4002, CH. It employs 17,995 people and is led by Wolfgang Wienand. In Q2 FY2026 it reported revenue of $4.04B and net income of $708M. The market values it at $46.1B.
What do the latest results show for Lonza Group AG (LZAGF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $4.04B. Against analyst estimates the company has EPS beat 3 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $4.39B Jan 28, 2026
- Latest report · revenue estimate
- $5.01B Jan 28, 2026
- Latest report · revenue vs estimate
- Below estimate Jan 28, 2026
- Latest report · EPS vs estimate
- Below estimate Jan 28, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jan 28, 2026 | $4.39B | $5.01B | $10.5500 | $11.9800 |
| Jul 23, 2025 | $4.50B | $4.40B | $7.6400 | $8.9000 |
| May 14, 2025 | $4.39B | $5.01B | $10.5500 | $11.9800 |
| Jul 25, 2024 | $4.51B | $4.40B | $9.4700 | $8.9000 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $4.04B | $708M | $10.12 (diluted) |
| Q4 FY2025 | $3.56B | $582M | -$12.05 (diluted) |
| Q2 FY2025 | $4.31B | $513M | $7.32 (diluted) |
| Q4 FY2024 | $4.24B | $370M | $5.19 (diluted) |
What are the financial strengths and risks for Lonza Group AG (LZAGF)?
Short answer
The distress and quality screens read Altman Z 4.31 · Piotroski F 7. Trailing ratios: ROE -1.3% · ROA -0.6% · current ratio 1.66 · earnings yield -0.3% · free-cash-flow yield 0.4%.
Data-derived red flags
- Negative return on equity (-1.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
Common Questions About LZAGF (Healthcare)
These answers are editorial: 1 of these 8 answers is drawn from the LZAGF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is LZAGF a good stock to buy?
Stock Expert AI does not rate LZAGF buy, sell or hold. Lonza Group AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LZAGF stock price today?
The last price recorded on this page for Lonza Group AG (LZAGF) is $660.00, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for LZAGF?
Lonza Group AG faces several key risks inherent to its position as a CDMO in the healthcare sector. A primary risk is its reliance on the success and progression of client pipelines; if client drug candidates fail in clinical trials or are deprioritized, Lonza could experience contract cancellations or reduced demand for its manufacturing services.
What are the key factors to evaluate for LZAGF?
Evaluate LZAGF on fundamentals, analyst consensus, and risk factors. **Expansion in Biologics CDMO Services**: The global demand for biopharmaceuticals continues to surge, driven by advancements in biotechnology and an aging global population. Not financial advice.
How frequently does LZAGF data refresh on this page?
LZAGF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LZAGF's recent stock price performance?
Lonza Group AG (LZAGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global leadership in contract development and manufacturing for biologics, small molecules, and cell & gene therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LZAGF overvalued or undervalued right now?
Lonza Group AG (LZAGF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LZAGF before investing?
Before investing in Lonza Group AG (LZAGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (39 figures)
The 39 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Wolfgang Wienand (Jul 22, 2026): Until 2030, based on our organic growth model, we intend to invest more than CHF 7 billion in organic CapEx, with the majority of it dedicated to future growth. Wolfgang Wienand (Jul 22, 2026): However, we anticipate that this will be offset in H2 due to the extended shutdown to progress with the site's CapEx measures, with full year 2026 sales expected to be broadly flat versus full year 2025 at around CHF 0.6 billion. Wolfgang Wienand (Jul 22, 2026): When we think about our future, we will look at full year 2026, which again, according to our upgraded guidance, will be another year of strong, profitable growth. Then we will actually continue our business planning in line with our organic growth model, which has low teens CER sales growth year-over-year on average over time, with profitability margins expanding over time as well. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 31 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $660.00 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T00:34:45.845Z. | |
px.change | Change on the day | -3.26% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $46.1B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T00:34:44.924Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Lonza Group AG, established in 1897 and based in Basel, Switzerland, is a global enterprise that furnishes critical products and services to the pharmaceutical, biotechnology, and nutrition sectors. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$22.21 | FMP | Financial Modeling Prep (FMP) · quote | |
px.range52 | 52-week range | $565.14–$755.96 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 27 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.84 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Muenchensteinerstrasse 38, Basel, BS, 4002, CH | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 17,995 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Wolfgang Wienand | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $4.04B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $708M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-01-28.revenue_actual | Revenue · reported — report date 2026-01-28 | $4.39B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-28.revenue_estimated | Revenue · estimate — report date 2026-01-28 | $5.01B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-28.eps_actual | EPS · reported — report date 2026-01-28 | $10.5500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-28.eps_estimated | EPS · estimate — report date 2026-01-28 | $11.9800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-23.revenue_actual | Revenue · reported — report date 2025-07-23 | $4.50B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-23.revenue_estimated | Revenue · estimate — report date 2025-07-23 | $4.40B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-23.eps_actual | EPS · reported — report date 2025-07-23 | $7.6400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-23.eps_estimated | EPS · estimate — report date 2025-07-23 | $8.9000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-14.revenue_actual | Revenue · reported — report date 2025-05-14 | $4.39B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-14.revenue_estimated | Revenue · estimate — report date 2025-05-14 | $5.01B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-14.eps_actual | EPS · reported — report date 2025-05-14 | $10.5500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-05-14.eps_estimated | EPS · estimate — report date 2025-05-14 | $11.9800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-07-25.revenue_actual | Revenue · reported — report date 2024-07-25 | $4.51B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-07-25.revenue_estimated | Revenue · estimate — report date 2024-07-25 | $4.40B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-07-25.eps_actual | EPS · reported — report date 2024-07-25 | $9.4700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-07-25.eps_estimated | EPS · estimate — report date 2024-07-25 | $8.9000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-08-20 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 4.31 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -1.3% · ROA -0.6% · current ratio 1.66 · earnings yield -0.3% · free-cash-flow yield 0.4% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $6.39 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.97% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-01-28.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($4.39B) with the recorded estimate ($5.01B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-01-28.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($10.5500) with the recorded estimate ($11.9800) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
Fact-family notes
- Earnings-history note. Source series as of 2026-01-28. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-01-28.revenue_actual,earn.history.depth.2026-01-28.revenue_estimated,earn.history.depth.2026-01-28.revenue_actual.comparison,earn.history.depth.2026-01-28.eps_actual.comparison,earn.history.depth.2026-01-28.eps_actual,earn.history.depth.2026-01-28.eps_estimated,earn.history.depth.2025-07-23.revenue_actual,earn.history.depth.2025-07-23.revenue_estimated,earn.history.depth.2025-07-23.eps_actual,earn.history.depth.2025-07-23.eps_estimated,earn.history.depth.2025-05-14.revenue_actual,earn.history.depth.2025-05-14.revenue_estimated,earn.history.depth.2025-05-14.eps_actual,earn.history.depth.2025-05-14.eps_estimated,earn.history.depth.2024-07-25.revenue_actual,earn.history.depth.2024-07-25.revenue_estimated,earn.history.depth.2024-07-25.eps_actual,earn.history.depth.2024-07-25.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.